{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:41:52Z","timestamp":1750524112386,"version":"3.41.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100023554","name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias","doi-asserted-by":"publisher","award":["PIFIISC22\/35"],"award-info":[{"award-number":["PIFIISC22\/35"]}],"id":[{"id":"10.13039\/501100023554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06339-5","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T03:35:05Z","timestamp":1743996905000},"page":"3007-3009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular response with asciminib 20\u00a0mg QD in a patient intolerant to multiple TKIs"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-2290","authenticated-orcid":false,"given":"Ruth","family":"Stuckey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Navarrete Bull\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-5614","authenticated-orcid":false,"given":"Asunci\u00f3n","family":"Borrero Borrego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Vidal Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rodr\u00edguez-Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Morales Curbelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Gonz\u00e1lez Pinedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5465-3355","authenticated-orcid":false,"given":"Melissa","family":"Torres Ochando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Veiga Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9649-4050","authenticated-orcid":false,"given":"Mar\u00eda del Mar","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-1445","authenticated-orcid":false,"given":"Cristina","family":"Bilbao-Sieyro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4862-4088","authenticated-orcid":false,"given":"Juan Francisco","family":"L\u00f3pez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-3227","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Segura-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-5126","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"4","key":"6339_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013684","journal-title":"Leukemia"},{"issue":"4","key":"6339_CR2","first-page":"209","volume":"3","author":"S Kurtin","year":"2012","unstructured":"Kurtin S (2012) Myeloid toxicity of cancer treatment. J Adv Pract Oncol 3(4):209\u2013224","journal-title":"J Adv Pract Oncol"},{"issue":"12","key":"6339_CR3","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G (2012) Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 53(12):2351\u20132361","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6339_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cncr.11863","volume":"100","author":"TB Sneed","year":"2004","unstructured":"Sneed TB, Kantarjian HM, Talpaz M, O\u2019Brien S, Rios MB, Bekele BN et al (2004) The significance of myelosuppression during therapy with Imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100(1):116\u2013121","journal-title":"Cancer"},{"key":"6339_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543:733\u2013737","journal-title":"Nature"},{"issue":"21","key":"6339_CR6","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S et al (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031\u20132041","journal-title":"Blood"},{"key":"6339_CR7","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1200\/JCO.2022.40.16_suppl.7004","volume":"40","author":"D Rea","year":"2022","unstructured":"Rea D, Mauro MJ, Hochhaus A, Boquimpani C, Lomaia E, Voloshin S et al (2022) Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after \u2265\u20092 prior tyrosine kinase inhibitors (TKIs): week 96 update. J Clin Oncol 40:7004\u20137004 (2022)","journal-title":"J Clin Oncol"},{"issue":"24","key":"6339_CR8","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ et al (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326","journal-title":"N Engl J Med"},{"issue":"2","key":"6339_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-021-00420-8","volume":"11","author":"V Garcia-Guti\u00e9rrez","year":"2021","unstructured":"Garcia-Guti\u00e9rrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B et al (2021) Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J 11(2):16","journal-title":"Blood Cancer J"},{"issue":"4","key":"6339_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/cancers15041045","volume":"15","author":"L P\u00e9rez-Lamas","year":"2023","unstructured":"P\u00e9rez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, P\u00e9rez L\u00f3pez R et al (2023) Toxicity of asciminib in real clinical practice: analysis of side effects and Cross-Toxicity with tyrosine kinase inhibitors. Cancers (Basel) 15(4):1045","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06339-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:45Z","timestamp":1749105465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06339-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6339"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06339-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for reporting individual cases or case series. This case was reported according to the CARE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Verbal informed consent was obtained from the patient for their anonymized information to be published in this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}